4Torresi J, Bharadwaj M, Jackson DC, Gowans EJ. Neutralising antibody, CTL and dendritic cell responses to hepatitis C virus: a preventative vaccine strategy. Curr Drug Targets 2004;5:41-56.
5Inchauspe G, Feinstone S. Development of a hepatitis C virus vaccine. Clin Liver Dis 2003;7:243-259.
6Forns X, Bukh J, Purcell RH. The challenge of developing a vaccine against hepatitis C virus. J Hepatol 2002;37:684-695.
7Leroux-Roels G, Depla E, Hulstaert F, Tobback L, Dincq S,Desmet J, Desombere I, Maertens G. A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers. Vaccine 2004;22:3080-3086.
8Puig M, Major ME, Mihalik K, Feinstone SM. Immunization of chimpanzees with an envelope protein-based vaccine enhances specific humoral and cellular immune responses that delay hepatitis C virus infection. Vaccine 2004;22:991-1000.
9Duenas-Carrera S, Vina A, Martinez R, Alvarez-Lajonchere L,Alvarez-Obregon JC, Marante J, Perez A, Mosqueda O,Martinez G, Morales J. Immunization with a DNA vaccine encoding the hepatitis-C-virus structural antigens elicits a specific immune response against the capsid and envelope proteins in rabbits and Macaca irus (crab-eating macaque monkeys). Biotechnol Appl Biochem 2004;39:249-255.
10Rollier C, Depla E, Drexhage JA, Verschoor EJ, Verstrepen BE,Fatmi A, Brinster C, Fournillier A, Whelan JA, Whelan M,Jacobs D, Maertens G, Inchauspe G, Heeney JL. Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral Thelper immune response. J Virol 2004;78:187-196.
